Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a Tumor's genes reveal the best treatment path?

NCT ID NCT02306096

Knowledge-focused Sponsor: Lund University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 27, 2026 · Last updated Aug 28, 2026 · Updated 1 time

Summary

This large Swedish study collects tumor samples from 20,000 people with breast cancer to map their genetic profiles. Researchers will analyze RNA and DNA to link gene patterns with patient outcomes, such as survival and response to therapy. The goal is to develop new molecular diagnostic tests that could guide more personalized treatment decisions.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to new molecular diagnostic tests that help doctors tailor breast cancer treatment based on a tumor's genetic profile.
What could go wrong
This is an observational study, not a treatment trial, so it won't directly test new therapies. The findings may take years to translate into clinical tools, and not all genetic markers will prove useful.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 20,000 people

The number the study aims to enrol. It can still change while the study runs.

Start date

Aug 2010

Expected to finish

Aug 2031

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

All patients with suspected or confirmed diagnosis of primary breast cancer within participating hospital systems in the South Sweden Healthcare Region, Uppsala County, and Jönköping Country, Sweden. Additional hospital sites from within the Nordic countries are welcome to join.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * suspicion or confirmed diagnosis of primary breast cancer * signed informed consent Exclusion Criteria: * lack of signed informed consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm Neoplasm, Residual Neoplastic Cells, Circulating

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast neoplasms

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    10 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Blekinge County Hospital

    RECRUITING

    Karlskrona, 37185, Sweden

  • Central Hospital Kristianstad

    RECRUITING

    Kristianstad, 29185, Sweden

  • Central Hospital Växjö

    RECRUITING

    Vaxjo, 35234, Sweden

  • Hallands Hospital Halmstad

    SUSPENDED

    Halmstad, 30233, Sweden

  • Helsingborg Hospital

    RECRUITING

    Helsingborg, 25187, Sweden

  • Kirurgiska kliniken

    SUSPENDED

    Jönköping, 55185, Sweden

  • Skåne University Hospital

    RECRUITING

    Lund, 22185, Sweden

  • Skåne University Hospital

    RECRUITING

    Malmö, 20502, Sweden

  • Södra Älvsborg Hospital

    RECRUITING

    Borås, Sweden

  • Uppsala University Hospital

    RECRUITING

    Uppsala, 75185, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.